When Characteristics of Clinical Trials Require Per-Protocol as Well as Intention-to-Treat Outcomes to Draw Reliable Conclusions (2023)

Peer-Reviewed Study · Scheim DE, Aldous C, Osimani B, Fordham EJ, Hoy WE · June 2023

Scheim DE et al., 2023-06: A methods paper by ivermectin's academic defenders arguing that the TOGETHER trial's intention-to-treat analysis masks a ten-fold mortality reduction visible in per-protocol analysis, and that the trial authors refused to disclose per-protocol outcomes.

The second RCT found a ten-fold reduction in mortality for a COVID-19 treatment drug vs. placebo by PP analysis, but only a minor benefit by ITT analysis.

Scheim DE et al., 2023-06: A methods paper by ivermectin's academic defenders arguing that the TOGETHER trial's intention-to-treat analysis masks a ten-fold mortality reduction visible in per-protocol analysis, and that the trial authors refused to disclose per-protocol outcomes. Methodological commentary (not a trial). Its three exemplar RCTs are the colonoscopy screening trial, TOGETHER's ivermectin arm, and another arm of the same platform. The authors argue that high protocol non-compliance justifies per-protocol reporting and that data transparency was refused. Declared: 'The authors declare no conflict of interest.' This is the published form of the pro-ivermectin critique of the negative trials (analysis choice), and it sits opposite IVE-49 to IVE-51 on the same trials. Bearing SUPPORTS is relative to C5's first half (published criticisms of the negative trials exist and are substantive), not an endorsement.